You are here: Industry Insights > BlueRock

News List

R&D Alliance for Eye Disease Cell Therapies contractpharma
May 18, 2021
BlueRock Therapeutics, Fujifilm Cellular Dynamics, and Opsis Therapeutics enter R&D pact to discover and develop cell therapies for eye diseases.
Bayer transforms pharma business through breakthrough innovation in healthcare worldpharmanews
January 18, 2021
At its virtual Pharma Media Day, Bayer presented exciting progress in transforming its pharmaceutical business with breakthrough innovation in healthcare that will significantly help patients suffering from conditions that are currently still ...
BlueRock, Sloan Kettering Receive IND Clearance for DA01 for Parkinson’s Disease americanpharmaceuticalreview
January 14, 2021
BlueRock Therapeutics, a wholly-owned subsidiary of Bayer AG, in collaboration with Memorial Sloan Kettering Cancer Center (MSK), announced the U.S. Food and Drug Administration (FDA) has cleared their Investigational New Drug (IND) application to ...
Bayer agrees to acquire biotech BlueRock for $1bn pharmaceutical-technology
August 09, 2019
German multinational pharmaceutical company Bayer has signed an agreement to acquire US-based biotechnology company BlueRock Therapeutics.
Bayer acquires BlueRock Therapeutics to build leading position in cell therapy worldpharmanews
August 09, 2019
Bayer AG and BlueRock Therapeutics today announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on...
Editas and BlueRock partner to develop engineered cell medicines pharmaceutical-technology
April 23, 2019
Editas and BlueRock partner to develop engineered cell medicines.